<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335435</url>
  </required_header>
  <id_info>
    <org_study_id>15-0179</org_study_id>
    <nct_id>NCT04335435</nct_id>
  </id_info>
  <brief_title>Avenanthramide and Saponin Bioavailability in Oat Bran</brief_title>
  <official_title>Avenanthramide and Saponin Bioavailability in Oat Bran</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Carolina Agriculture &amp; Technical State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Carolina Agriculture &amp; Technical State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Avenanthramides and saponins are types of chemical compounds found naturally in oats.&#xD;
&#xD;
      Avenanthramides have anti-oxidant properties, anti-atherosclerotic, anti-inflammation, and&#xD;
      anti-proliferative effects on cancer cells in vitro. Oat saponins, or avenacosides, have the&#xD;
      ability to bind cholesterol, and thus, the ability to lower blood cholesterol.&#xD;
&#xD;
      Oat bran is a known source of these dietary compounds. This study aims to determine the&#xD;
      bioavailability of these compounds to in the urine of participants after ingesting an oat&#xD;
      bran cereal, both before, and after for multiple time points.&#xD;
&#xD;
      Analytical chemistry will be used to determine the bioavailability of the oat compounds at&#xD;
      each time point. This will help to establish a kinetic curve for the metabolism of these&#xD;
      compounds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initially, the diet of the participants will be asked to restricted to avoid eating any&#xD;
      polyphenols that might interfere with the employed analytical chemistry techniques. This&#xD;
      period of diet restriction is the washout period. The list of foods to avoid are: oats, whole&#xD;
      grains, fruits, vegetables, herbal supplements, ginger, coffee, tea, and chocolate.&#xD;
&#xD;
      After the washout period, a baseline urine and fecal sample will be collected from the&#xD;
      participants, then a large portion of oat bran will be provided to the participants for&#xD;
      consumption. The approximate portion size will be 100 g by dry weight. The participants will&#xD;
      then provide urine samples during the designated time points. The time points for the urine&#xD;
      collection are as follows:&#xD;
&#xD;
        1. st sample, ~ 30 min to 1 hour prior to oat consumption&#xD;
&#xD;
        2. nd sample: 0-2 hours after oat consumption&#xD;
&#xD;
        3. rd sample: 2-4 hours after oat consumption&#xD;
&#xD;
        4. th sample: 4-6 hours after oat consumption&#xD;
&#xD;
        5. th sample: 6-9 hours after oat consumption&#xD;
&#xD;
        6. th sample: 9-12 hours after oat consumption&#xD;
&#xD;
        7. th sample: 12-24 hours after oat consumption&#xD;
&#xD;
        8. th sample: 24-32 hours after oat consumption&#xD;
&#xD;
        9. th sample: 48 hours after oat consumption These samples will be analyzed in using HPLC&#xD;
           and LC/MS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Actual">January 21, 2016</completion_date>
  <primary_completion_date type="Actual">January 21, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>0-2 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>2-4 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>4-6 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>6-9 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>9-12 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>12-24 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>24-32 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability of Avenanthramides and Saponins in Urine</measure>
    <time_frame>32-48 hours post-dose</time_frame>
    <description>Liquid chromatography-tandem mass spectrometry will be utilized to assess the bioavailability of avenanthramides and saponins in urine.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Human Health</condition>
  <condition>Polyphenols</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Oat Bran Consumption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject consumed 120 g of oat bran (by dry weight) in a single dose, and samples (urine and fecal) were collected at different time points following the administration of oat bran.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oat Bran Consumption</intervention_name>
    <description>Oat bran (120 g), single dose.</description>
    <arm_group_label>Oat Bran Consumption</arm_group_label>
    <other_name>Gut Microbiome and Oat metabolism Study</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18.5-25&#xD;
&#xD;
          -  Have blood and urine biochemical markers in normal range&#xD;
&#xD;
          -  Have no known allergy to oat relate foods&#xD;
&#xD;
          -  Be not taking antibiotics for six months&#xD;
&#xD;
          -  Be not currently taking medication&#xD;
&#xD;
          -  Be nonsmoking&#xD;
&#xD;
          -  Have no alcoholic intoxication&#xD;
&#xD;
          -  Have no extensive exposure to industrial waste&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with gout&#xD;
&#xD;
          -  Individuals with heart disease&#xD;
&#xD;
          -  Individuals with peripheral vascular diseases&#xD;
&#xD;
          -  Individuals with degenerative liver&#xD;
&#xD;
          -  Cancer patients&#xD;
&#xD;
          -  Patients with diabetes&#xD;
&#xD;
          -  Individuals with GI disorders&#xD;
&#xD;
          -  Individuals with endocrine disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengmin Sang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Carolina Agriculture and Technical State University</affiliation>
  </overall_official>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Carolina Agriculture &amp; Technical State University</investigator_affiliation>
    <investigator_full_name>Shengmin Sang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Avenanthramides</keyword>
  <keyword>Saponins</keyword>
  <keyword>bioavailability</keyword>
  <keyword>polyphenols</keyword>
  <keyword>oat bran</keyword>
  <keyword>pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

